These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31172597)

  • 21. Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.
    Xia X; Liu Y; Liao Y; Guo Z; Huang C; Zhang F; Jiang L; Wang X; Liu J; Huang H
    Eur J Pharmacol; 2019 Aug; 856():172409. PubMed ID: 31132355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations.
    Pallis A; Briasoulis E; Linardou H; Papadimitriou C; Bafaloukos D; Kosmidis P; Murray S
    Curr Med Chem; 2011; 18(11):1613-28. PubMed ID: 21428885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities.
    Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH
    Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor.
    Rong X; Liang Y; Han Q; Zhao Y; Jiang G; Zhang X; Lin X; Liu Y; Zhang Y; Han X; Zhang M; Luo Y; Li P; Wei L; Yan T; Wang E
    J Thorac Oncol; 2019 Oct; 14(10):1766-1783. PubMed ID: 31228625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors.
    Thomas R; Srivastava S; Katreddy RR; Sobieski J; Weihua Z
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31121829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
    Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
    Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Vinyl Sulfone Derivatives as EGFR Tyrosine Kinase Inhibitor: In Vitro and In Silico Studies.
    Aiebchun T; Mahalapbutr P; Auepattanapong A; Khaikate O; Seetaha S; Tabtimmai L; Kuhakarn C; Choowongkomon K; Rungrotmongkol T
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33921332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. V843I, a lung cancer predisposing EGFR mutation, is responsible for resistance to EGFR tyrosine kinase inhibitors.
    Matsushima S; Ohtsuka K; Ohnishi H; Fujiwara M; Nakamura H; Morii T; Kishino T; Goto H; Watanabe T
    J Thorac Oncol; 2014 Sep; 9(9):1377-84. PubMed ID: 25057940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
    Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
    Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
    Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
    J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy.
    Cha YK; Lee HY; Ahn MJ; Choi YL; Lee JH; Park K; Lee KS
    Clin Lung Cancer; 2015 May; 16(3):228-36. PubMed ID: 25499173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Irreversible EGFR inhibitors in the treatment of advanced NSCLC.
    Maione P; Rossi A; Bareschino M; Sacco PC; Schettino C; Casaluce F; Sgambato A; Gridelli C
    Curr Pharm Des; 2014; 20(24):3894-900. PubMed ID: 24138713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure.
    Yamaoka T; Ohba M; Arata S; Ohmori T
    J Vis Exp; 2017 Aug; (126):. PubMed ID: 28829429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-Targeted Nanoparticles Deliver a Vitamin D-Based Drug Payload for the Treatment of EGFR Tyrosine Kinase Inhibitor-Resistant Lung Cancer.
    Liu C; Shaurova T; Shoemaker S; Petkovich M; Hershberger PA; Wu Y
    Mol Pharm; 2018 Aug; 15(8):3216-3226. PubMed ID: 29902012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas.
    Zhang B; Wang S; Qian J; Yang W; Qian F; Lu J; Zhang Y; Qiao R; Han B
    Cancer; 2018 Jun; 124(11):2399-2406. PubMed ID: 29543321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer.
    Li Y; Song Z; Jin Y; Tang Z; Kang J; Ma X
    Molecules; 2016 Nov; 21(11):. PubMed ID: 27827863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer.
    Morgillo F; Amendola G; Della Corte CM; Giacomelli C; Botta L; Di Maro S; Messere A; Ciaramella V; Taliani S; Marinelli L; Trincavelli ML; Martini C; Novellino E; Ciardiello F; Cosconati S
    J Med Chem; 2017 Sep; 60(17):7447-7458. PubMed ID: 28787156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.